PRESS RELEASE

Visit link:
Immunocore Announces Pricing of Upsized Initial Public Offering

Truthfinder is a background check service designed to allow one to perform searches on any person. Check out our review. Truthfinder is a background check service designed to allow one to perform searches on any person. Check out our review.

See the article here:
Truthfinder Review – Background Checker Product Review by Mike Vaughn

Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology

Originally posted here:
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in...

Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER

Read more:
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Pratteln, Switzerland, February 5, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 1,600,000 treasury shares. The number of shares recorded in the commercial register has been increased to 21,029,696 shares.

Read more from the original source:
Santhera Completes Capital Increase for Financing Arrangements

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.

The rest is here:
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director

Message from the CEO

Here is the original post:
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020

Please read the full announcement in PDF

Read the original post:
Trading by management and close relations of management

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

See the article here:
Silence Therapeutics plc Announces $45 Million Private Placement

Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product

Link:
Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product

OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM’s Equity Distribution Agreement (EDA). Management believes, based on the company’s current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund current clinical trials over approximately the next twenty-four months.

See the article here:
AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials

NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming virtual investor conferences.

See the original post here:
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at 2:00 p.m. ET. The conference will be held in a virtual meeting format.

Continued here:
IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day

Strengthened Financial Position Supports Execution into the First Half of 2023 Strengthened Financial Position Supports Execution into the First Half of 2023

Visit link:
Orchard Therapeutics Announces $150 Million Strategic Financing

CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD).

Continue reading here:
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.

See the article here:
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

Read the original:
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints

Go here to read the rest:
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 103,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

See more here:
GBT Announces New Employment Inducement Grants

Go here to see the original:
Bespoke Extracts Welcomes Trend Expert Carly Stojsic as New Director of Marketing